Acadian Asset Management
PDSB icon

Acadian Asset Management’s PDS Biotechnology PDSB Stock Holding History

Acadian Asset Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-61,793
Closed -$61K – 2083
2025
Q3 		$61K Buy
+61,793
New +$72.6K ﹤0.01% 1613

Other funds holding PDSB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management's PDSB Position: Q4 2025 in Review

Acadian Asset Management sold out of PDS Biotechnology (PDSB) in Q4 2025, closing a stake of 61,793 shares — an estimated $61K sold.

Acadian Asset Management first reported a position in PDSB in Q3 2025 and held it in 1 quarter. The position peaked at $61K in Q3 2025. 44 funds tracked by Wall St. Rank hold PDSB as of Q4 2025.

  • Acadian Asset Management reported no remaining PDS Biotechnology position as of Q4 2025 after selling out during the quarter.
  • Acadian Asset Management sold 61,793 PDS Biotechnology shares in Q4 2025, an estimated $61K.
  • Acadian Asset Management first reported a position in PDS Biotechnology in Q3 2025 and held it in 1 quarter.
  • Acadian Asset Management's PDS Biotechnology position peaked at $61K in Q3 2025.
  • 44 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2025.

Based on Acadian Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.